Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Consensus Rating of “Moderate Buy” by Brokerages

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) has earned an average rating of “Moderate Buy” from the fifteen ratings firms that are covering the company, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $76.67.

A number of equities analysts recently issued reports on the stock. Raymond James raised their price objective on shares of Apellis Pharmaceuticals from $67.00 to $106.00 and gave the stock a “strong-buy” rating in a report on Thursday, January 11th. Robert W. Baird reaffirmed an “outperform” rating and set a $81.00 price target on shares of Apellis Pharmaceuticals in a report on Tuesday, February 6th. Wedbush decreased their price target on Apellis Pharmaceuticals from $67.00 to $57.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. Needham & Company LLC restated a “buy” rating and set a $85.00 target price on shares of Apellis Pharmaceuticals in a research report on Wednesday. Finally, Oppenheimer upped their price target on shares of Apellis Pharmaceuticals from $75.00 to $79.00 and gave the company an “outperform” rating in a research note on Tuesday, January 30th.

Apellis Pharmaceuticals Stock Up 0.5 %

Shares of Apellis Pharmaceuticals stock opened at $42.52 on Friday. The stock has a market capitalization of $5.16 billion, a PE ratio of -12.29 and a beta of 0.97. Apellis Pharmaceuticals has a 52-week low of $19.83 and a 52-week high of $94.75. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.50 and a current ratio of 3.10. The company has a 50-day simple moving average of $53.91 and a two-hundred day simple moving average of $57.32.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings data on Tuesday, May 7th. The company reported ($0.54) earnings per share for the quarter, meeting the consensus estimate of ($0.54). The firm had revenue of $172.33 million during the quarter, compared to analysts’ expectations of $163.37 million. Apellis Pharmaceuticals had a negative net margin of 133.34% and a negative return on equity of 178.60%. The firm’s quarterly revenue was up 284.3% on a year-over-year basis. During the same period in the previous year, the company earned ($1.56) earnings per share. On average, analysts anticipate that Apellis Pharmaceuticals will post -1.27 EPS for the current fiscal year.

Insider Activity

In other news, insider Adam J. Townsend sold 1,148 shares of the business’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $67.77, for a total value of $77,799.96. Following the completion of the sale, the insider now owns 92,453 shares in the company, valued at approximately $6,265,539.81. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Apellis Pharmaceuticals news, insider Adam J. Townsend sold 1,148 shares of the stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $67.77, for a total transaction of $77,799.96. Following the completion of the sale, the insider now directly owns 92,453 shares of the company’s stock, valued at $6,265,539.81. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, General Counsel David O. Watson sold 781 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $67.77, for a total transaction of $52,928.37. Following the completion of the sale, the general counsel now owns 103,390 shares of the company’s stock, valued at $7,006,740.30. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 455,334 shares of company stock worth $26,511,351. Company insiders own 7.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Wynnefield Capital Inc. acquired a new stake in Apellis Pharmaceuticals during the 3rd quarter valued at approximately $380,000. abrdn plc acquired a new position in Apellis Pharmaceuticals during the fourth quarter valued at $10,119,000. General American Investors Co. Inc. purchased a new stake in Apellis Pharmaceuticals in the third quarter valued at $1,712,000. Profund Advisors LLC grew its position in Apellis Pharmaceuticals by 114.5% during the 3rd quarter. Profund Advisors LLC now owns 35,153 shares of the company’s stock worth $1,337,000 after purchasing an additional 18,766 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Apellis Pharmaceuticals by 6.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 879,357 shares of the company’s stock valued at $33,451,000 after buying an additional 50,835 shares during the last quarter. Institutional investors and hedge funds own 96.29% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).